alpha-Synucleinopathy models and human neuropathology: similarities and differences.
about
Multiple system atrophy: a clinical and neuropathological perspectiveAdult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticityImpaired c-Fos and polo-like kinase 2 induction in the limbic system of fear-conditioned α-synuclein transgenic miceParkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration.Localization of synucleins in the mammalian cochleaMyelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma.Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy.Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophyStructure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicityVersatile somatic gene transfer for modeling neurodegenerative diseases.rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.Modelling progressive autonomic failure in MSA: where are we now?A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degenerationRegulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers.α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein.Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy.Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.alpha-Synuclein: a therapeutic target for Parkinson's disease?Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons.The role of microglia in synaptic stripping and synaptic degeneration: a revised perspective.Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration.Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology.α-Synuclein in Parkinson's disease.Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.α-Synuclein and neuronal cell death.Toxic species in amyloid disorders: Oligomers or mature fibrils.Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy.Mutant alpha-synuclein overexpression mediates early proinflammatory activity.Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders.Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption.Conserved core of amyloid fibrils of wild type and A30P mutant α-synuclein.Therapeutic implication of autophagy in neurodegenerative diseases.Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy.Neurobehavioral Anomalies in the Pitx3/ak Murine Model of Parkinson's Disease and MPTP.Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9.The effects of apolipoprotein E genotype, α-synuclein deficiency, and sex on brain synaptic and Alzheimer's disease-related pathology.p62 Deficiency Enhances α-Synuclein Pathology in Mice.Emerging Disease-Modifying Strategies Targeting α-Synuclein for the Treatment of Parkinson Disease.
P2860
Q26829838-6F7EC96B-7C51-477F-978B-2CF3639F59DDQ26862840-24207298-D01A-4306-BFB8-D77EFC706774Q27334377-4E2A4EC8-1F9A-4D3A-882E-47C357900879Q27348827-10EEFD27-0DA7-4BB4-81A6-823285D736B8Q30484963-481F2A4B-0DB4-4266-8E89-94E301DD01E5Q30497967-6DB13A07-0702-40F2-B38E-B2307E5F44C6Q30499509-29D1C38C-7453-4421-BB60-BCDF2D67F6ECQ33914242-411A55F6-EB7C-44B4-B0E0-039BDE9226E9Q34003885-B4BCC5D5-A60B-432C-B4BE-A52444DB374AQ34285870-2A118C22-28FB-454E-B80C-F2A49055DC85Q34465572-6EAFF636-476C-484F-9F63-599499428880Q34626244-59833568-5D75-4BF7-A7DB-59D3A6E02553Q34989985-4E3DDF39-FDB9-4014-B99C-765E98DC9118Q34995420-DF568209-A061-4ABA-A1EF-B953BB4F5DD8Q35658734-102ACF92-EDF5-4DD2-93CF-FBC67F0A3603Q35674483-68767BAF-9082-49F3-BF33-90806CBB5655Q36341144-245FC7B5-7BC9-4830-8A61-B03178BE6C36Q36454426-88F51E29-FE4E-4C33-A2E5-288ED3E10134Q36777244-93182A9E-7BE1-4D12-9E86-08E93E5CB774Q37070916-154C2291-4DC6-4885-9CB2-A5164F43CE72Q37294051-5B652DEA-9973-444B-B6B4-4D4631171006Q37802202-753AF279-705F-4987-B431-9E113364C553Q37873359-7592E801-2E77-424E-BCB3-739540C703E8Q37959310-583F70D8-AF82-4A27-83F6-7C5B68B519F3Q37987146-D2B9B651-51C9-4F1B-93D9-BEC2ADC8AC94Q38000327-A7B66490-BF78-455A-BE9D-61F347285132Q38039369-21051B54-02B9-486D-969D-4B9206B26DDAQ38505323-520154CD-072A-4E14-A4F2-F860AE216A3BQ39268815-ED11A7E0-F932-4D1A-AEE8-71345F3267F2Q40778644-D22F3C67-5E4E-4A6D-ACFB-810C984A5AC0Q41597801-FBF16D35-49CE-44EE-977E-AF0EAE7A4354Q41827902-F7BE07B3-FFAC-4823-B359-6E86F61C60F7Q41845690-B1BD43A0-FDE4-4116-A0A8-4B00D1CA2719Q42353908-A69F55F8-0987-4439-BB75-EB099298E512Q42449176-AC446BED-79EF-413D-9082-4B285EE049A0Q42483926-89A635A0-38AD-453A-B721-E85B10FC8A7AQ43577652-CDAF8800-362E-43FF-857B-81945B530E09Q47107297-568FBA3F-0CB2-48A5-8FB0-A208A4DE3044Q48451250-B2D9BFBD-FE49-4F5E-B88F-1E2AB6233FC4Q52714245-A3434FD6-3704-4866-96B0-4DD75E6551A0
P2860
alpha-Synucleinopathy models and human neuropathology: similarities and differences.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
alpha-Synucleinopathy models and human neuropathology: similarities and differences.
@en
type
label
alpha-Synucleinopathy models and human neuropathology: similarities and differences.
@en
prefLabel
alpha-Synucleinopathy models and human neuropathology: similarities and differences.
@en
P2860
P1476
alpha-Synucleinopathy models and human neuropathology: similarities and differences.
@en
P2093
Philipp J Kahle
P2860
P2888
P356
10.1007/S00401-007-0302-X
P577
2007-10-12T00:00:00Z